Marta Bellini

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

Elisa Rumi, Daniela Pietra, Virginia Valeria Ferretti et al. · Blood · 2013 · 585 citations · Full text

Medicine, Genetics, Hematology +13

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Elisa Rumi, Daniela Pietra, Cristiana Pascutto et al. · Blood · 2014 · 383 citations · Full text

Medicine, Genetics, Hematology +16

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial

Tiziano Barbui, Alessandro M. Vannucchi, Valerio De Stefano et al. · The Lancet Haematology · 2021 · 132 citations · Full text

Medicine, Hematology, Pharmacotherapy +6

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui, Alessandro M. Vannucchi, Alberto Álvarez‐Larrán et al. · Leukemia · 2021 · 82 citations · Full text

Medicine, Hematology, Pharmacology +15

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis

Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra et al. · Blood · 2014 · 72 citations · Full text

Medicine, Genetics, Hematology +11